An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial

Next Previous
Trial Profile

An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms EDEN Trial

    • Most Recent Events

    • 28 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top